Human Parvovirus B19 and Blood Products
Authors:
- 1 January 1997
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 72 (1) , 1-10
Abstract
Background and objectives: Human B19 parvovirus (B19), identified in 1975, was only recognised as the causative agent of fifth disease in 1983. The incidence of viraemia is low, around 1 in 1,000, but is sufficient to ensure that most plasma pools for fractionation contain some virus. While infection usually occurs in childhood and is benign, chronic infection sometimes occurs and may be of concern in certain patient groups. Materials and methods: This review is based on a meeting held in March 1995, and addresses recent concerns regarding the potential transmission of B19 infection by pooled plasma products. Results: Recent data on the pathophysiology and assay of this virus are summarised along with possible approaches to donor screening, product screening, and virus removal. Only five cases of symptomatic infection have been reported in persons with haemophilia, but no technology for virus removal is established, and infection may be of concern in pregnant women, and in patients with enhanced red cell turnover or who are immunosuppressed, including those infected with human immunodeficiency virus, but only rarely in immunocompetent patients. Conclusions: For the future, well‐validated assays relevant to virus infectivity are required if blood donations, plasma pools, or plasma products are to be screened, and an in‐process virus inactivation step for B19 would be highly desirable. In the interim, non‐plasma or recombinant products or a selective transfusion policy might be used in patient groups in which B19 infection is of particular concern. Further clinical data on the prognosis and impact of B19 infection are needed to justify both such policies and the future adoption of new technologies designed to reduce any excess B19 infectivity arising from transfused products.Keywords
This publication has 112 references indexed in Scilit:
- Transfusion‐transmitted human parvovirus B19 infection in a thalassemic patientTransfusion, 1995
- Persistent parvovirus B19 infectionThe Lancet, 1995
- B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentratesThe Lancet, 1994
- Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patientEuropean Journal of Clinical Microbiology & Infectious Diseases, 1993
- Human parvovirus B19-associatedarthritis in childrenThe Journal of Pediatrics, 1993
- Removal of parvovirus B19 from contaminated factor VIII during fractionationJournal of Medical Virology, 1991
- Human Parvovirus B19New England Journal of Medicine, 1989
- Pure Red-Cell Aplasia of 10 Years' Duration Due to Persistent Parvovirus B19 Infection and Its Cure with Immunoglobulin TherapyNew England Journal of Medicine, 1989
- Human Parvo Virus B19 Infection among Hospital Staff Members after Contact with Infected PatientsNew England Journal of Medicine, 1989
- TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 1983